77265-67-9

Basic information

• Product Name: METHYL 4-(2-AMINO-ETHYL)-BENZOATE
• Synonyms: METHYL 4-(2-AMINO-ETHYL)-BENZOATE;RARECHEM AN KA 0188;Benzoic acid, 4-(2-aMinoethyl)-, Methyl ester;2-(4-carboMethoxyphenyl)ethanaMine;Methyl 4-(2-amino-ethyl)-benzate
• CAS NO: 77265-67-9
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.22
• Mol File: 77265-67-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 292.8±23.0 °C(Predicted)
• Appearance: /
• Density: 1.093±0.06 g/cm3(Predicted)
• PKA: 9.56±0.10(Predicted)
• CAS DataBase Reference: METHYL 4-(2-AMINO-ETHYL)-BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-(2-AMINO-ETHYL)-BENZOATE(77265-67-9)
• EPA Substance Registry System: METHYL 4-(2-AMINO-ETHYL)-BENZOATE(77265-67-9)

Safety Data

• Hazardous Substances Data: 77265-67-9(Hazardous Substances Data)

Usage

General Description

Methyl 4-(2-amino-ethyl)-benzoate is a chemical compound with the molecular formula C10H13NO2. It is also known by the name Anthranilic acid, N-2-methylphenethyl ester. It is used in the synthesis of pharmaceuticals and as an intermediate in the production of various compounds. The compound is a white solid at room temperature and is soluble in most organic solvents. It is important to handle this chemical with caution, as it may cause irritation to the respiratory system, skin, and eyes upon exposure.

Upstream product

• 76469-88-0 methyl 4-(cyanomethyl)benzoate 
• 99-75-2 4-methyl-benzoic acid methyl ester 
• 67-56-1 methanol 
• 132690-91-6 4-[2-(tert-butyloxycarbonylamino)ethyl]benzoic acid 
• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 120157-97-3 t-butyl 2-(4-bromophenyl)ethylcarbamate 
• 73918-56-6 4-Bromophenethylamine 
• 60531-36-4 4-(2-amino-ethyl)-benzoic acid hydrochloride 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 

Downstream Products

• 223768-45-4 methyl 4-(N-benzyl-2-aminoethyl)benzoate 
• 467439-23-2 4-(2-{(R)-2-[(S)-2-((S)-4-Carboxy-2-isobutoxycarbonylamino-butyrylamino)-4-methyl-pentanoylamino]-3-mercapto-propionylamino}-ethyl)-benzoic acid methyl ester 
• 647376-15-6 4-(4-methoxycarbonylphenethylamino)-6-nitroquinazoline 
• 1025878-38-9 4-[2-((S)-2-Amino-4-phenyl-butyrylamino)-ethyl]-benzoic acid methyl ester 
• 202652-97-9 4-{2-[(S)-2-(2-Hydroxycarbamoyl-4-methyl-pentanoylamino)-4-phenyl-butyrylamino]-ethyl}-benzoic acid methyl ester 
• 1026475-72-8 4-{2-[(S)-2-(2-Benzyloxycarbamoyl-4-methyl-pentanoylamino)-4-phenyl-butyrylamino]-ethyl}-benzoic acid methyl ester 
• 724705-97-9 4-[2-(5,6-Dihydroxy-hexanoylamino)-ethyl]benzoic Acid Methyl Ester 
• 1093938-00-1 methyl 4-(2-(methylamino)ethyl)benzoate 
• 1093938-72-7 methyl 4-(2-(2,2,2-trifluoro-N-methylacetamido)ethyl)benzoate 
• 64353-30-6 4-(2-aminoethyl)-benzyl alcohol 
• 132690-91-6 4-[2-(tert-butyloxycarbonylamino)ethyl]benzoic acid 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

Synthesis and study of new quinolineaminoethanols as anti-bacterial drugs

The lack of antibiotics with a novel mode of action associated with the spread of drug resistant bacteria make the fight against infectious diseases particularly challenging. A quinoline core is found in several anti-infectious drugs, such as mefloquine and bedaquiline. Two main objectives were set in this work. Firstly, we evaluated the anti-mycobacterial properties of the previous quinolines 3, which have been identified as good candidates against ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli) bacteria. Secondly, a new series 4 was designed and assessed against the same bacteria strains, taking the pair of enantiomers 3m/3n as the lead. More than twenty compounds 4 were prepared through a five-step asymmetric synthesis with good enantiomeric excesses (>90%). Interestingly, all compounds of series 3 were efficient on M. avium with MIC = 2–16 μg/mL, while series 4 was less active. Both series 3 and 4 were generally more active than mefloquine against the ESKAPEE bacteria. The quinolines 4 were either active against Gram-positive bacteria (MIC ≤ 4 μg/mL for 4c–4h and 4k/4l) or E. coli (MIC = 32–64 μg/mL for 4q–4v) according to the global lipophilicity of these compounds.

MTH1 INHIBITORS FOR TREATMENT OF CANCER

A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.